Initiation of lenacapavir with dose escalation in a patient receiving rifabutin: A case report with therapeutic drug monitoring

Lenacapavir is a first‐in‐class HIV‐1 capsid inhibitor with long‐acting pharmacokinetics that enable 6‐monthly subcutaneous dosing after initiation with oral lead‐in. Lenacapavir is a CYP3A4, UGT1A1 and P‐gp substrate; inducers of these enzymes and P‐gp can significantly decrease lenacapavir concentrations. In patients receiving lenacapavir for HIV pre‐exposure prophylaxis (PrEP), supplemental lenacapavir doses can be administered if rifabutin (moderate inducer) or rifampin (potent inducer) are initiated. However, these recommendations have not been extended to lenacapavir when used for HIV treatment, and little is known about initiating lenacapavir in patients on stable therapy with inducers. We describe a 30‐year‐old man with advanced HIV infection and disseminated Mycobacterium avium complex infection receiving rifabutin and concurrent darunavir/ritonavir in whom lenacapavir was initiated with a 50% increase in both oral (900 mg on Days 1 and 2) and subcutaneous loading doses (1390.5 mg on Day 1). Therapeutic drug monitoring using validated UPLC–MS/MS method demonstrated that lenacapavir plasma concentrations remained above the target of 15.5 ng/mL (4× protein‐adjusted 95% effective concentration [PA‐EC 95 ]) over the dosing interval, with C max of 245.7 ng/mL and a projected C min of 19.5 ng/mL at 6 months. HIV viral load remained suppressed. This case demonstrates that dose‐adjusted lenacapavir can achieve therapeutic exposures in the presence of pre‐existing moderate induction. These findings provide clinically relevant pharmacological insight to support the use of lenacapavir in complex patients requiring rifamycin therapy.

Authors

Institutions

Publication Details

Journal
British Journal of Clinical Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.1002/bcp.70932
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Initiation of lenacapavir with dose escalation in a patient receiving rifabutin: A case report with therapeutic drug monitoring

Amanda K. Hempel, Catia Marzolini, Aaron S. Devanathan, Alexandra Cheung et al.
1 links
British Journal of Clinical Pharmacology
HIV/AIDS drug development and treatment
article

Initiation of lenacapavir with dose escalation in a patient receiving rifabutin: A case report with therapeutic drug monitoring

Amanda K. Hempel, Catia Marzolini, Aaron S. Devanathan, Alexandra Cheung, Alice Lin-In Tseng, Felix Leung, Mark T. McIntyre
article en

Abstract

Lenacapavir is a first‐in‐class HIV‐1 capsid inhibitor with long‐acting pharmacokinetics that enable 6‐monthly subcutaneous dosing after initiation with oral lead‐in. Lenacapavir is a CYP3A4, UGT1A1 and P‐gp substrate; inducers of these enzymes and P‐gp can significantly decrease lenacapavir concentrations. In patients receiving lenacapavir for HIV pre‐exposure prophylaxis (PrEP), supplemental lenacapavir doses can be administered if rifabutin (moderate inducer) or rifampin (potent inducer) are initiated. However, these recommendations have not been extended to lenacapavir when used for HIV treatment, and little is known about initiating lenacapavir in patients on stable therapy with inducers. We describe a 30‐year‐old man with advanced HIV infection and disseminated Mycobacterium avium complex infection receiving rifabutin and concurrent darunavir/ritonavir in whom lenacapavir was initiated with a 50% increase in both oral (900 mg on Days 1 and 2) and subcutaneous loading doses (1390.5 mg on Day 1). Therapeutic drug monitoring using validated UPLC–MS/MS method demonstrated that lenacapavir plasma concentrations remained above the target of 15.5 ng/mL (4× protein‐adjusted 95% effective concentration [PA‐EC 95 ]) over the dosing interval, with C max of 245.7 ng/mL and a projected C min of 19.5 ng/mL at 6 months. HIV viral load remained suppressed. This case demonstrates that dose‐adjusted lenacapavir can achieve therapeutic exposures in the presence of pre‐existing moderate induction. These findings provide clinically relevant pharmacological insight to support the use of lenacapavir in complex patients requiring rifamycin therapy.

British Journal of Clinical Pharmacology
Mount Sinai Hospital (CA), University Health Network (CA), University of Liverpool (GB), University of Pittsburgh (US), University of Toronto (CA), Centre Hospitalier Universitaire Vaudois (CH), Sinai Health System (CA), University of Lausanne (CH)
Good health and well-being
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon